Revenues totaled $71.4 million for the quarter, up 11 percent over last year's $64.1 million during the same period. Of this, $37.4 million came from Bruker Daltonics, Bruker's mass spec business, up 7 percent from $34.9 million during the last year's second quarter. About 70 percent of the Daltonics revenues stem from mass spec systems for life sciences.
The company's research and development costs increased slightly, to $11 million, from $10.3 million during the second quarter of 2004.
Bruker reported a net income of $284,000, or $0 per share, up from a net loss of $4.4 million, or $.05 per share, for the same period last year.
As of June 30, Bruker had $92 million in cash and short-term investments.